# A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors

> **NCT04207463** · PHASE2 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 150 (estimated)

## Conditions studied

- Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors

## Interventions

- **DRUG:** AK105
- **DRUG:** Anlotinib

## Key facts

- **NCT ID:** NCT04207463
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06-03
- **Primary completion:** 2020-12-31
- **Final completion:** 2021-05-30
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2020-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04207463

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04207463, "A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04207463. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*